Brokerages Set LeMaitre Vascular Inc (LMAT) PT at $34.50
Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) have received a consensus recommendation of “Hold” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $34.50.
LMAT has been the subject of several analyst reports. Zacks Investment Research downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, November 10th. BidaskClub downgraded LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Saturday, December 2nd. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $33.00 price target on shares of LeMaitre Vascular in a report on Friday, February 23rd.
In other news, CEO George W. Lemaitre sold 5,700 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $35.56, for a total transaction of $202,692.00. Following the completion of the sale, the chief executive officer now directly owns 3,259,263 shares in the company, valued at approximately $115,899,392.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 42,036 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $35.68, for a total value of $1,499,844.48. Following the sale, the chief executive officer now owns 3,259,263 shares of the company’s stock, valued at $116,290,503.84. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company’s stock.
Shares of LeMaitre Vascular (NASDAQ:LMAT) traded up $1.00 on Thursday, reaching $35.15. The company’s stock had a trading volume of 107,104 shares, compared to its average volume of 135,073. The firm has a market cap of $677.16, a P/E ratio of 41.35, a PEG ratio of 2.40 and a beta of 0.55. LeMaitre Vascular has a 52 week low of $21.87 and a 52 week high of $39.88.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $26.15 million during the quarter, compared to the consensus estimate of $26.23 million. LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. LeMaitre Vascular’s revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.13 EPS. analysts expect that LeMaitre Vascular will post 0.98 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 5th. Stockholders of record on Thursday, March 22nd will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.80%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.06. The ex-dividend date of this dividend is Wednesday, March 21st. LeMaitre Vascular’s dividend payout ratio is presently 25.88%.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.